Last reviewed · How we verify
parenteral nutrition
Parenteral nutrition delivers a balanced mixture of carbohydrates, proteins, lipids, vitamins, and minerals intravenously to provide complete nutritional support when oral or enteral feeding is not possible.
Parenteral nutrition delivers a balanced mixture of carbohydrates, proteins, lipids, vitamins, and minerals intravenously to provide complete nutritional support when oral or enteral feeding is not possible. Used for Nutritional support in patients unable to tolerate oral or enteral feeding, Short bowel syndrome, Severe malabsorption disorders.
At a glance
| Generic name | parenteral nutrition |
|---|---|
| Also known as | intravenous feeding |
| Sponsor | Hospices Civils de Lyon |
| Drug class | Nutritional support therapy |
| Modality | Small molecule |
| Therapeutic area | Nutritional support / Critical care |
| Phase | FDA-approved |
Mechanism of action
Parenteral nutrition (PN) is a sterile intravenous formulation that bypasses the gastrointestinal tract to supply essential macronutrients (amino acids, dextrose, lipid emulsions) and micronutrients (electrolytes, vitamins, trace elements) directly into the bloodstream. This allows patients with severe malabsorption, bowel obstruction, or other conditions preventing normal feeding to maintain adequate nutritional status and support metabolic function.
Approved indications
- Nutritional support in patients unable to tolerate oral or enteral feeding
- Short bowel syndrome
- Severe malabsorption disorders
- Bowel obstruction or ileus
- Critical illness with feeding intolerance
Common side effects
- Catheter-related bloodstream infection
- Hyperglycemia
- Hepatic dysfunction / cholestasis
- Refeeding syndrome
- Electrolyte imbalances
- Thrombophlebitis
Key clinical trials
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
- Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections (PHASE2)
- PROGAIN Trial in Gastric Cancer Surgery (PHASE3)
- Prospective Multisite Study of Quality of Life in Pediatric Intestinal Failure
- PICU-related Sleep and Circadian Dysregulation Pilot Study (NA)
- Natural Killer Cells and Bortezomib to Treat Cancer (PHASE1)
- Optimizing Early Nutrition Support in Severe Stroke-2 (PHASE3)
- Effect of a Parenteral Emulsion With Omega3 on Neonates With PPHN and CDH (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- parenteral nutrition CI brief — competitive landscape report
- parenteral nutrition updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI